TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Learning and Coping Strategies in Cardiac Rehabilitation - A Randomised Controlled Parallel Group Study
Brief Summary: Background: It is well known that cardiac rehabilitation has potential to reduce morbidity and mortality, but not all patients complete CR. This LC-REHAB trial aims to compare the effect of a new patient education method called learning and coping strategies to that of standard care.

Design: Randomised controlled trial, 1:1 ratio. Participants: Patients above 18 years newly hospitalised with either ischaemic heart disease or heart failure.

Setting: Three hospital Units in Central Denmark Region. Intervention: Cardiac rehabilitation with addition of learning and coping strategies which include participation of experienced patients as co-educators, clarifuing interviews, and inductive teaching style.

Control arm: Standard care cardiac rehabilitation with a decuctive teaching style.

Outcomes: Adherence to cardiac rehabilitation, morbidity, mortality, risk factors, lifestyle, health related quality of life, return to work.


Options:
A: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management
B: Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
C: Arm Label: PBL- patient education; Type: EXPERIMENTAL; Interventions: Behavioral: PBL in patient education, Behavioral: Mailed patient information | Arm Label: Mailed patient information; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed patient information | Intervention Type: BEHAVIORAL; Name: PBL in patient education; Assigned to Arm(s): PBL- patient education | Intervention Type: BEHAVIORAL; Name: Mailed patient information; Assigned to Arm(s): Mailed patient information, PBL- patient education
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group | Intervention Type: BEHAVIORAL; Name: Intervention Group; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Learning and Coping Strategies in Cardiac Rehabilitation - A Randomised Controlled Parallel Group Study
Brief Summary: Background: It is well known that cardiac rehabilitation has potential to reduce morbidity and mortality, but not all patients complete CR. This LC-REHAB trial aims to compare the effect of a new patient education method called learning and coping strategies to that of standard care.

Design: Randomised controlled trial, 1:1 ratio. Participants: Patients above 18 years newly hospitalised with either ischaemic heart disease or heart failure.

Setting: Three hospital Units in Central Denmark Region. Intervention: Cardiac rehabilitation with addition of learning and coping strategies which include participation of experienced patients as co-educators, clarifuing interviews, and inductive teaching style.

Control arm: Standard care cardiac rehabilitation with a decuctive teaching style.

Outcomes: Adherence to cardiac rehabilitation, morbidity, mortality, risk factors, lifestyle, health related quality of life, return to work.


Options:
A: Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
B: Arm Label: Hospital-based; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Shared care Model; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shared Care model | Intervention Type: BEHAVIORAL; Name: Shared Care model; Assigned to Arm(s): Shared care Model
C: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
D: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Brief Summary: The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy


Options:
A: Arm Label: A-immunotherapy; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa-2a, Drug: Interleukin-2 | Arm Label: B-follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interferon Alfa-2a; Assigned to Arm(s): A-immunotherapy | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): A-immunotherapy
B: Arm Label: 1: AGS-003+sunitinib; Type: EXPERIMENTAL; Interventions: Biological: AGS-003, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): 1: AGS-003+sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1: AGS-003+sunitinib
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: Arm 1: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm 2: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm 1: Nivolumab | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm 2: Everolimus

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Brief Summary: The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy


Options:
A: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: Arm 1: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm 2: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm 1: Nivolumab | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm 2: Everolimus

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
Brief Summary: The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.


Options:
A: Arm Label: BI 409306 dose 1; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 2; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 3; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 dose 1, BI 409306 dose 2, BI 409306 dose 3
B: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole (OPC-34712); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole (OPC-34712) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hatha Yoga for Patients With Colorectal Cancer - a Randomized Controlled Trial
Brief Summary: Hatha Yoga is a traditional practice that encompasses aerobic exercise, breathing techniques, and meditation. It is used in India since centuries to improve well-being and cope with diseases and is gaining more and more interest in Europe and the US. While studies have demonstrated benefits of Hatha Yoga for patients with breast cancer, no studies on patients with colorectal cancer are available yet. The purpose of this study is to investigate the effect of Hatha Yoga in patients with colorectal cancer.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Digital Health Physical Activity Intervention Group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Digital Health Physical Activity Intervention Group; Assigned to Arm(s): Intervention
B: Arm Label: Hatha yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Hatha yoga | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hatha yoga; Assigned to Arm(s): Hatha yoga
C: Arm Label: Stressmanagement counselling; Type: OTHER; Interventions: Other: Stressmanagement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stressmanagement; Assigned to Arm(s): Stressmanagement counselling
D: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: complementary or alternative medicine procedure; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fatigue assessment and management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: physical therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
Brief Summary: This study seeks to evaluate a low-literacy strategy in a primary health care setting for promoting safe and effective prescription medication use among English and Spanish-speaking patients with diabetes.

The investigators hypothesize that in comparison with patients receiving standard care, the patients that received the Electronic Health Record (EHR) strategy will 1) demonstrate better understanding of how to safely dose out their medication regimen; 2) have fewer discrepancies in their medication lists; 3) take their medication regimen more efficiently; 4) have greater adherence to their medication regimen.


Options:
A: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
B: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2
D: Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
Brief Summary: This study seeks to evaluate a low-literacy strategy in a primary health care setting for promoting safe and effective prescription medication use among English and Spanish-speaking patients with diabetes.

The investigators hypothesize that in comparison with patients receiving standard care, the patients that received the Electronic Health Record (EHR) strategy will 1) demonstrate better understanding of how to safely dose out their medication regimen; 2) have fewer discrepancies in their medication lists; 3) take their medication regimen more efficiently; 4) have greater adherence to their medication regimen.


Options:
A: Arm Label: naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non-naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: non-naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Team-care deprescribing with deprescribing guide; Assigned to Arm(s): naive Deprescribing arm, non-naive Deprescribing arm
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Basic medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Basic medication therapy management | Arm Label: Enhanced medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced medication therapy management | Intervention Type: BEHAVIORAL; Name: Basic medication therapy management; Assigned to Arm(s): Basic medication therapy management | Intervention Type: BEHAVIORAL; Name: Enhanced medication therapy management; Assigned to Arm(s): Enhanced medication therapy management
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication, Behavioral: Systematic Pain Assessment and Treatment, Behavioral: Medication Review, Behavioral: Occupational therapy, Behavioral: Safety | Intervention Type: BEHAVIORAL; Name: Communication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Systematic Pain Assessment and Treatment; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication Review; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Safety; Assigned to Arm(s): Intervention
D: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Brief Summary: The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.


Options:
A: Arm Label: Group I; Type: N/A; Interventions: N/A | Arm Label: Group II; Type: N/A; Interventions: N/A
B: Arm Label: Bifidobacterium animalis lactis Bl-04; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bifidobacterium lactis Bl-04, Biological: Rhinovirus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Biological: Rhinovirus | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis Bl-04; Assigned to Arm(s): Bifidobacterium animalis lactis Bl-04 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Rhinovirus; Assigned to Arm(s): Bifidobacterium animalis lactis Bl-04, Placebo
C: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Other: Yogurt drink with probiotic bacteria BB12 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Yogurt drink with probiotic bacteria BB12; Assigned to Arm(s): Probiotic | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control
D: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hellenic Anglo Research Into Morning Or Evening Antihypertensive Drug deliverY Trial
Brief Summary: A randomised crossover trial of anti-hypertensive medication dosing regimen in effective blood pressure control.

To investigate whether there is a difference in 24 hour blood pressure (BP) control when antihypertensive medications are taken in the morning compared with the evening.


Options:
A: Arm Label: Evening medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Medication - | Arm Label: Morning medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Medication - | Intervention Type: DRUG; Name: Anti-hypertensive Medication -; Assigned to Arm(s): Evening medication, Morning medication
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): 1, 2 | Intervention Type: DEVICE; Name: ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2

Answer: A